Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016:2016:7310694.
doi: 10.1155/2016/7310694. Epub 2016 Jul 4.

Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis

Chengcheng Hao  1 , Zhiyan Wang  1 , Yanan Gu  1 , Wen G Jiang  2 , Shan Cheng  1
Affiliations
Meta-Analysis

Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis

Chengcheng Hao et al. Biomed Res Int. 2016.

Abstract

Objectives. Osteopontin (OPN) is overexpressed in breast cancers, while its clinical and prognostic significance remained unclear. This study aimed to assess the prognostic value of OPN, especially its splice variants, in breast cancers. Methods. Data were extracted from eligible studies concerning the OPN and OPN-c expression in breast cancer patients and were used to calculate the association between OPN/OPN-c and survival. Two reviewer teams independently screened the literatures according to the inclusion and exclusion criteria based on quality evaluation. Following the processes of data extraction, assessment, and transformation, meta-analysis was carried out via RevMan 5.3 software. Results. A total of ten studies involving 1,567 patients were included. The results demonstrated that high level OPN indicated a poor outcome in the OS (HR = 2.22, 95% CI: 1.23-4.00, and P = 0.008; random-effects model) with heterogeneity (I (2) = 62%) of breast cancer patients. High level OPN-c appeared to be more significantly associated with poor survival (HR = 2.14, 95% CI: 1.51-3.04, and P < 0.0001; fixed-effects model) with undetected heterogeneity (I (2) = 0%). Conclusions. Our analyses indicated that both OPN and OPN-c could be considered as prognostic markers for breast cancers. The high level of OPN-c was suggested to be more reliably associated with poor survival in breast cancer patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the selection process of studies for inclusion in this meta-analysis.
Figure 2
Figure 2
Forest plot demonstrating the association of OPN expression with overall survival in breast cancer. HR, hazard ratio; CI, confidence interval.
Figure 3
Figure 3
Forest plot on the association between OPN expression and overall survival in breast cancer by sensitivity analysis. HR, hazard ratio; CI, confidence interval.
Figure 4
Figure 4
Forest plot demonstrating the association of OPN expression with overall survival in tissues of breast cancer patients. HR, hazard ratio; CI, confidence interval.
Figure 5
Figure 5
Forest plot demonstrating the association of OPN expression with overall survival in blood of breast cancer patients. HR, hazard ratio; CI, confidence interval.
Figure 6
Figure 6
Forest plot demonstrating the association of OPN-c expression with overall survival in breast cancer. HR, hazard ratio; CI, confidence interval.
Figure 7
Figure 7
Begg's funnel plot estimating the publication bias of the included studies about OPN. HR, hazard ratio.
Figure 8
Figure 8
Begg's funnel plot estimating the publication bias of the included studies about OPN-c. HR, hazard ratio.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DeSantis C. E., Fedewa S. A., Sauer A. G., Kramer J. L., Smith R. A., Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA: A Cancer Journal for Clinicians. 2016;66(1):31–42. doi: 10.3322/caac.21320. - DOI - PubMed
    1. Fan L., Strasser-Weippl K., Li J.-J., et al. Breast cancer in China. The Lancet Oncology. 2014;15(7):e279–e289. doi: 10.1016/S1470-2045(13)70567-9. - DOI - PubMed
    1. Anborgh P. H., Caria L. B. R., Chambers A. F., Tuck A. B., Stitt L. W., Brackstone M. Role of plasma osteopontin as a biomarker in locally advanced breast cancer. American Journal of Translational Research. 2015;7(4):723–732. - PMC - PubMed
    1. Martinetti A., Bajetta E., Ferrari L., et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocrine-Related Cancer. 2004;11(4):771–779. doi: 10.1677/erc.1.00775. - DOI - PubMed
    1. Singhal H., Bautista D. S., Tonkin K. S., et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research. 1997;3(4):605–611. - PubMed

Publication types